Adebrelimab: Clinical Trials

101 trials of Adebrelimab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

45 recruiting, 41 not yet recruiting, 11 unknown, 2 active not recruiting. 101 Phase 2, 10 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 2101Recruiting 45, Not yet recruiting 41, Unknown 11, Active not recruiting 2, Completed 1, Suspended 1
Phase 110Recruiting 4, Not yet recruiting 2, Unknown 2, Active not recruiting 1, Completed 1
Phase 31Recruiting 1

Follow Adebrelimab: new trials by email Literature Review of Adebrelimab trials Research Report on Adebrelimab

Trials (filtered) newest first · largest first

All 101 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Exploratory Study of Short-Course Radiotherapy Followed by Adebrelimab Combined With Chemotherapy for Organ Preservation in Locally Advanced Rectal Cancer
Adebrelimab - Locally Advanced Resectable Rectal Cancer
Phase 2Not yet recruitingHenan Cancer Hospital1552026-11-012026-10-30
An Open, Multicenter Phase II Clinical Trial of SHR-A2009 Combined With Other Anti-tumor Therapies for Perioperative Treatment of Resectable Non-small Cell Lung Cancer.
adebrelimab + SHR-A2009, paclitaxel or pemetrexed combined with carboplatin +adebrelimab, adebrelimab - Non-small Cell Lung Cancer
Phase 2Not yet recruitingSuzhou Suncadia Biopharmaceuticals Co., Ltd.6602026-10-302026-11-09
Adebrelimab Plus Famitinib as Adjuvant Therapy in Non-pCR NSCLC
Adebrelimab, Adjuvant treatment - Lung Neoplasm Malignant
Phase 2Not yet recruitingRuijin Hospital642026-10-202026-10-22
Adebrelimab Plus Temozolomide ± Hyperbaric Oxygen for Primary Glioblastoma
Adebrelimab, Temozolomide, Procedure:Hyperbaric Oxygen Therapy - Glioblastoma
Phase 2Not yet recruitingWei Jiang942026-10-012026-08-27
Perioperative Adebrelimab for Locally Advanced Cervical Cancer
Adebrelimab, Paclitaxel, Cisplatin - Locally Advanced Cervical Cancer
Phase 2Not yet recruitingAnhui Provincial Hospital352026-10-012026-09-10
Response-Guided Bladder Preservation With Trastuzumab Rezetecan, Adebrelimab, and Concurrent Bladder Radiotherapy in HER2-Expressing Muscle-Invasive Bladder Cancer
Trastuzumab Rezetecan, Adebrelimab, Concurrent Bladder Radiotherapy - Muscle-Invasive Bladder Cancer (MIBC)
Phase 2Not yet recruitingTongji Hospital702026-09-012026-10-08
Trastuzumab Rezetecan and Adebrelimab, Alone or in Combination, After Chemoradiotherapy for HER2-Altered Unresectable Stage III Lung Cancer
Trastuzumab Rezetecan (SHR-A1811) + Adebrelimab, Trastuzumab Rezetecan (SHR-A1811), Adebrelimab - Non-Small Cell Lung Cancer
Phase 2Not yet recruitingMing Chen1052026-09-012026-09-23
Clinical Study of Radiotherapy Combined With Adebrelimab and NALIRIFOX for Conversion Therapy in Locally Advanced Pancreatic Cancer
Adebrelimab (PD-L1 inhibitor), NALIRIFOX, SBRT - Pancreatic Ductal Adenocarcinoma (PDAC)
Phase 2Not yet recruitingShanghai General Hospital, Shanghai Jiao Tong University School of Medicine362026-09-012026-09-18
Study of Adebrelimab Combined With Thymalfasin and Chemotherapy for Neoadjuvant Treatment of Esophageal Cancer
Adebrelimab, Thymalfasin, Chemotherapy - Esophageal Cancer
Phase 2Not yet recruitingThe Affiliated Hospital of Putian University312026-08-302026-08-21
A Prospective Phase II Clinical Trial Evaluating the Efficacy and Safety of Adebrelimab in Combination With Trastuzumab Rezetecan for Patients With Stage III Unresectable HER2-Positive NSCLC
Adebrelimab, Trastuzumab rezetecan - NSCLC
Phase 2Not yet recruitingTianjin Medical University Cancer Institute and Hospital372026-08-202026-08-21
A Pan-RAS Inhibitor in Combination With Anti-Tumor Therapy in Participants With Advanced Pancreatic Cancer
HRS-2329 Tablet, Nimotuzumab, HS-20093 - Pancreatic Cancer, RAS Mutations or Amplifications
Phase 1 / Phase 2Not yet recruitingZhejiang University802026-08-152026-08-31
PRaG-1 Plus PRaG Therapy in in Elderly Patients With Advanced Solid Tumors: A Prospective Clinical Trial (PRaG 10.0)
Adebrelimab - Solid Cancer, Lymphopenia
Phase 2RecruitingSecond Affiliated Hospital of Soochow University652026-08-102026-11-12
Neoadjuvant Short-course Hypofractionated Radiotherapy Plus Adebrelimab and Platinum Chemotherapy in Locally Advanced Cervical Cancer: A Single-arm Phase II Trial
Adebrelimab - Cervical Neoplasms
Phase 2RecruitingThe First Affiliated Hospital with Nanjing Medical University352026-08-012026-07-28
Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCC
Adebrelimab, Nab paclitaxel, Carboplatin - Esophageal Cancer
Phase 2RecruitingTianjin Medical University Cancer Institute and Hospital1202026-07-312026-07-29
Low-dose Thoracic Radiotherapy Followed by Adebrelimab Plus Chemotherapy, and Then Sequential Maintenance Therapy With Adebrelimab for Extensive-stage Small Cell Lung Cancer
Etoposide, Cisplatin, Carboplatin - Lung, Radiotherapy
Phase 2RecruitingJiangmen Central Hospital432026-07-202026-09-22
Neoadjuvant Radio-immunotherapy Versus Immunotherapy Alone for Locally Advanced HNSCC
Adebrelimab, radiotherapy - Head and Neck Squamous Cell Carcinoma, Locally Advanced Head and Neck Squamous Cell Carcinoma
Phase 2Not yet recruitingChen Chunyan362026-05-012026-04-28
Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib as First-Line Therapy for Advanced HER2-Positive/HER2-Low Biliary Tract Cancer
Trastuzumab Rezetecan, Adebrelimab, Lenvatinib - Biliary Tract Neoplasms Immunotherapy
Phase 2RecruitingPeking Union Medical College Hospital702026-04-292026-06-26
Adebrelimab Plus S-1 for Resected Cholangiocarcinoma
Adebrelimab, S-1 - Cholangiocarcinoma, Biliary Tract Cancer
Phase 2Not yet recruitingXingjun Guo402026-04-212026-05-01
Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib in Advanced HER2-Positive/Low-Expression Biliary Tract Cancer
Trastuzumab Rezetecan, Adebrelimab, Lenvatinib - Biliary Tract Neoplasms Immunotherapy
Phase 2RecruitingPeking Union Medical College Hospital702026-04-152026-07-15
Efficacy and Safety of Low-dose Bevacizumab Plus Adebrelimab Combined With Transarterial Chemoembolization Followed by Hepatic Arterial Infusion Chemotherapy (TACE-HAIC) as First-line Treatment for Unresectable Hepatocellular Carcinoma: A Single-arm Phase 2 Trial
Transarterial Chemoembolization (TACE), Hepatic Arterial Infusion Chemotherapy (HAIC, FOLFOX), Adebrelimab - Adebrelimab (SHR-1316), Bevacizumab
Phase 2Not yet recruitingThird Affiliated Hospital, Sun Yat-Sen University382026-04-102026-04-28

Showing 20 of 101. Sign in to see all of them.

Conditions studied

Small Cell Lung Carcinoma (8)  ·  Biliary Tract Neoplasms (7)  ·  Carcinoma, Non-Small-Cell Lung (7)  ·  Cholangiocarcinoma (5)  ·  Esophageal Squamous Cell Carcinoma (5)  ·  Pancreatic Neoplasms (5)  ·  Stomach Neoplasms (5)  ·  Carcinoma, Hepatocellular (4)  ·  Breast Neoplasms (3)  ·  Esophageal Neoplasms (3)  ·  Squamous Cell Carcinoma of Head and Neck (3)  ·  Colorectal Neoplasms (2)  ·  Lung Neoplasms (2)  ·  Nasopharyngeal Carcinoma (2)  ·  Rectal Neoplasms (2)

Sponsors

The First Affiliated Hospital with Nanjing Medical University (7)  ·  Fudan University (6)  ·  Suzhou Suncadia Biopharmaceuticals Co., Ltd. (6)  ·  Tianjin Medical University Cancer Institute and Hospital (6)  ·  Fujian Cancer Hospital (4)  ·  Harbin Medical University (4)  ·  Henan Cancer Hospital (3)  ·  Shanghai Hengrui Pharmaceutical Co., Ltd. (3)  ·  Sun Yat-sen University (3)  ·  Tongji Hospital (3)  ·  Peking Union Medical College Hospital (2)  ·  The Affiliated Hospital of Putian University (2)  ·  The First Affiliated Hospital of Xiamen University (2)  ·  Zhangzhou Municipal Hospital (2)  ·  Air Force Military Medical University, China (1)

Countries

China (77)

Top investigators

Bo Liu, Professor (1)  ·  Changqing Jing, Professor (1)  ·  Chong Deng (1)  ·  Chunyan Chen (1)  ·  Da Chen, MD&PhD (1)  ·  Dezhi Li, MD&PhD (1)  ·  Fang Liu, MD (1)  ·  Feng Cheng, MD (1)  ·  Guangyuan Hu, Doctor (1)  ·  Guoqin Qiu (1)  ·  Hao Xu, Ph.D (1)  ·  Hecheng Li, MD, PhD (1)  ·  Hongxia Wang (1)  ·  Hongxia Wang, Chief physician (1)  ·  Huita Wu (1)

Results publications

PMID 29366520, PMID 32716739, PMID 36434949, PMID 36529152, PMID 37011232, PMID 39252865, PMID 41730557, PMID 41816563